

Dear xxx

**Freedom of Information request: Treatment of Diffuse Large B Cell Lymphoma (CORP 2024 – 133)**

Thank you for your request for information which the Trust received on 6<sup>th</sup> July 2024.

Your Request:

**Q1.** *In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?*

**Q1a.** *Of these patients, how many commenced treatment at your trust within the last 6 months?*

**Q2.** *In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:*

- *R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)*
- *R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)*
- *Pola-BR (polatuzumab vedotin with rituximab and bendamustine)*
- *Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)*
- *R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)*
- *R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)*
- *Axicabtagene ciloleucel (Yescarta)*
- *Tisagenlecleucel*
- *Epcoritamab*
- *Loncastuximab tesirine*
- *Glofitamab*
- *Any other SACT*
- *Stem cell transplant or bone marrow transplant (autologous or allogeneic)*

**Q3.** *In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):*

- *Axicabtagene ciloleucel (Yescarta)*
- *Tisagenlecleucel*
- *Pola-BR (polatuzumab vedotin with rituximab and bendamustine)*
- *Stem cell transplant or bone marrow transplant (autologous or allogeneic)*
- *Any other treatments*

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre  
Velindre University NHS Trust Headquarters  
2 Cwrt Charnwood  
Heol Billingsley  
Parc Nantgarw  
Caerdydd/Cardiff  
CF15 7QZ  
Ffôn/Phone : (029) 20196161  
<https://velindre.nhs.wales>



**Q4.** In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatment

**Q5.** Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

Please find the Trust's response below:

**Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**

**Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?**

Due to the nature of the services provided by the Trust, as explained below, we do not hold information relating to your request.

Velindre University NHS Trust is a nationally recognised specialist centre of excellence for the provision of non-surgical oncology including radiotherapy and chemotherapy; specialist palliative care; blood transfusion; specialist immunohaematology; antenatal blood testing reference work; and transplant immunology. The Trust provides a range of specialist non-surgical oncology services to approximately 1.5 million people of South-East Wales, and to the whole of Wales for some services, working in partnership with the hospitals managed by the Local Health Boards. The Welsh Blood Service collects processes and delivers blood and blood products to hospitals across Wales.


Please follow the link above to the Trusts internet site should you wish to find out more information about our services.

In relation to **questions 2-4**, there have been less than 6 patients treated for DLBCL. Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

**Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?**

There are currently no DLBCL trials running within the Trust.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk)  
Head of Information Governance  
Velindre University NHS Trust  
2, Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff, CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales  
2nd Floor  
Churchill House  
Churchill Way  
Cardiff  
CF10 2HH  
Telephone: 0330 414 6421  
email: [wales@ico.org.uk](mailto:wales@ico.org.uk)

Yours sincerely

**Non Gwilym**  
**Interim Director of Corporate Governance**  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

